Skip to main content
Premium Trial:

Request an Annual Quote

Guardant Inks Liquid Biopsy Assay Deal With Pfizer Oncology

NEW YORK (GenomeWeb) – Guardant Health announced late last week that it has signed an agreement to provide its Guardant360 liquid biopsy cancer assay to Pfizer's oncology business unit, for use in clinical trials.

Guardant360 is a blood-based 73-gene test that investigates actionable somatic alteration across all solid tumor sites to provide clinicians with information to better manage their patients' disease. Under the terms of the non-exclusive deal, the assay will be a Pfizer Oncology preferred circulating tumor DNA test for liquid biopsy specimens.

Additional terms of the deal were not disclosed.

Earlier this year, Guardant formed alliances with Pfizer and three other big pharma companies to develop a new 500-plus-gene liquid biopsy panel for use in clinical trials and cancer drug and immunotherapy development.

The Scan

Latent HIV Found in White Blood Cells of Individuals on Long-Term Treatments

Researchers in Nature Microbiology find HIV genetic material in monocyte white blood cells and in macrophages that differentiated from them in individuals on HIV-suppressive treatment.

Seagull Microbiome Altered by Microplastic Exposure

The overall diversity and the composition at gut microbiome sites appear to coincide with microplastic exposure and ingestion in two wild bird species, according to a new Nature Ecology and Evolution study.

Study Traces Bladder Cancer Risk Contributors in Organ Transplant Recipients

In eLife, genome and transcriptome sequencing reveal mutation signatures, recurrent somatic mutations, and risky virus sequences in bladder cancers occurring in transplant recipients.

Genes Linked to White-Tailed Jackrabbits' Winter Coat Color Change

Climate change, the researchers noted in Science, may lead to camouflage mismatch and increase predation of white-tailed jackrabbits.